Jupiter Life Line Hospitals Limited (JLHL) share price

₹279.15 on NSE as of 2026-09-11. -0.66% on the day. market cap ₹1,830 Cr. P/E 9.8. 52-week range ₹239.98 to ₹332.40. Healthcare.

Jupiter Life Line Hospitals Q1 FY27: Revenue Up 16.4%, Operating Profit Up 1.1%, and a ₹9.5 Crore Hospital That Just Opened

At a glance

Revenue for the quarter came in at ₹411 crore, up 16.4% from ₹353 crore a year ago. Operating profit came in at ₹79 crore, up 1.1% from ₹78 crore. Those two sentences are doing very different things, and the gap between them has a name and a postal address: Dombivli.

Management states the quarter's EBITDA carries an operational loss of ₹9.5 crore from the Dombivli hospital, which completed its first full quarter of operations, plus higher marketing costs tied to launch activity. Operating margin landed at 19% against 22% in the year-ago quarter — the first sub-20% print in the ten quarters on record.

PAT was ₹37.5 crore, down 14.6% year-on-year and down 25.3% from the March quarter. Depreciation climbed to ₹26 crore from ₹21 crore, which management attributes to capitalisation of newly added beds. Finance costs rose to ₹13 crore from ₹8 crore, which management attributes to debt taken for expansion projects.

Meanwhile, ARPOB — revenue per occupied bed — went to ₹73,500 from ₹67,300. The existing hospitals are charging more per bed and filling them at roughly the same rate. The new hospital is charging a construction bill against the P&L every single month.

In March, ICRA upgraded the long-term rating to [ICRA]AA- (Stable) from [ICRA]A+. In July, the board approved the results, appointed a new CFO, and noted that a subsidiary had bought a company with zero turnover and a plot of land near Ujjain.

Yes, we're getting to that.

Introduction

Jupiter Life Line Hospitals Limited, incorporated in 2007, is a multi-specialty tertiary and quaternary healthcare provider in the Mumbai Metropolitan Area and the western region of India. It operates four hospitals — Thane, Pune (Baner), Indore and Dombivli — with roughly 1,248 operational beds as of the latest disclosure, of which 140 are non-census beds.

The company came to market via an IPO that raised ₹869 crore, of which ₹542 crore was a fresh issue earmarked for repayment of borrowings and general corporate purposes. Look at the FY2024 balance sheet and you can see exactly where that money landed: reserves jumped from ₹309 crore to ₹1,103 crore and borrowings went to nil. It was, briefly, a debt-free hospital chain.

That interlude lasted one financial year. Borrowings were ₹393 crore in March 2025 and ₹584 crore in March 2026, because Jupiter decided that a listed hospital chain with a clean balance sheet was a terrible waste of a clean balance sheet.

The last eighteen months of filings read like a construction diary. In March 2025, a ₹350 crore loan agreement with HDFC Bank. In January 2026, the announcement that Dombivli was complete with 200 operational beds. In March 2026, MMRDA allotted roughly 10,026 sq m of BKC land on an 80-year lease against a one-time premium of about ₹354 crore, for a planned ~400-bed hospital. In May 2026, the board approved FY26 results, a ₹1 interim dividend, a 1:5 stock split, and Dr. Ajay Thakker's appointment as Chairman and Whole Time Director. Also in May 2026, CFO Sivasis Sen resigned from JLHL and JHPPL effective May 31.

By July 2026, a replacement was named: Harshad Purani, previously President – Administration, with the company since September 2007 and over twenty years of experience. He was, in other words, already in the building.

Business model

Jupiter runs big hospitals. Not many hospitals — big ones. Four facilities, and the operating philosophy is described in the filings as an "all-hub-no-spoke" model: each hospital is a full-service independent facility, equipped with its own specialists and infrastructure, serving its own catchment.

Most chains build one flagship and then scatter feeder clinics around it like breadcrumbs. Jupiter's approach is to build the flagship, then build another flagship, then look at the map and think about where the next flagship goes. Management on the call put it as: each one is designed as a full-scale hub, not a spoke, not a satellite.

The specialty list is the full tertiary-quaternary spread — cardiology, oncology, orthopaedics, neurology and neurosciences, organ transplant, nephrology, urology, haematology, endocrinology, paediatrics, and about eight more. Revenue splits into inpatient (~78.2%), outpatient (~17.3%) and others (~4.5%) on the most recent segment disclosure. The revenue engine is the occupied bed; everything else is the funnel that fills it.

Who pays? Insurance companies at 54.7% of the quarter's payor mix, self-payors at 44.4%, and government schemes at 0.9%. That last number is the one worth staring at. In a country where hospital chains often build entire operating models around government scheme volumes, Jupiter has essentially opted out.

Geography is Maharashtra with an Indore exception. Thane (~377 beds), Pune Baner (~309), Indore (~375), Dombivli (~200). Management describes the sizing logic as serving the immediate 45-minute driving distance community — a hospital, in this telling, is a very expensive neighbourhood amenity.

Notably absent: medical tourism. Management stated on the call that international patients contribute very little and that they don't find it particularly margin-accretive or necessary to focus on. While peers chase inbound cardiac patients with airport pickup services, Jupiter is content to treat people from Thane.

Quarterly results, balance sheet, cash flow, ratios, shareholding and the filings themselves are on the full page for Jupiter Life Line Hospitals Limited.

Companies in the same industry as Jupiter Life Line Hospitals Limited

Hospital

All listed companies